Etinamato
Etinamato Uses, Dosage, Side Effects, Food Interaction and all others data.
Etinamato is a short-acting sedative-hypnotic medication used to treat insomnia. Like many such similar medications, the regular use of ethinamate can result in the development of drug tolerance in a patient. Nevertheless, the medication itself is generally no longer effective after using it for greater than 7 days. Structurally, it does not resemble the barbituates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates.
Etinamato is used to treat insomnia (trouble in sleeping). However, it has generally been replaced by other medicines for the treatment of insomnia. If ethinamate is used regularly (for example, every day) to help produce sleep, it is usually not effective for more than 7 days. Structurally, it does not resemble the barbiturates, but it shares many effects with this class of drugs; the depressant effects of ethinamate are, however, generally milder than those of most barbiturates. Continued and inappropriate use of ethinamate can lead to tolerance and physical dependence, with withdrawal symptoms very similar to those of the barbiturates.
| Trade Name | Etinamato |
| Generic | Ethinamate |
| Ethinamate Other Names | Aethinyl-cyclohexyl-carbamat, Ethinamate, Ethinamatum, Etinamato |
| Type | |
| Formula | C9H13NO2 |
| Weight | Average: 167.205 Monoisotopic: 167.094628665 |
| Groups | Approved, Illicit, Withdrawn |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Used for the short-term treatment of insomnia, however, it generally has been replaced by other sedative-hypnotic agents.
How Etinamato works
The mechanism of action is not known. However, studies have shown that ethinamate inhibits carbonic anhydrases I and II (J Biol Chem. 1992 Dec 15;267(35):25044-50). This inhibition by ethinamate is not sufficiently strong, however, to implicate carbonic anhydrases I and II in the mechanism of action.
Toxicity
Symptoms of overdose include shortness of breath or slow or troubled breathing, slow heartbeat, severe weakness, chronic confusion, slurred speech, and staggering.
Elimination Route
Rapidly absorbed following oral administration.
Half Life
2.5 hours
Innovators Monograph
You find simplified version here Etinamato
